7th International Congress of Cardionephrology KARNEF (2025) [pp. 201-205]
AUTHOR(S) / АУТОР(И): Sebastjan Bevc 
, Robert Ekart, Radovan Hojs
Download Full Pdf 
DOI: 10.46793/KARNEF25.210B
ABSTRACT / САЖЕТАК:
The cardio-renal-metabolic (CRM) continuum is a concept that emphasizes the close interrelationship of cardiovascular, renal and metabolic disorders. These three components are crucial for an individual’s health and are often associated with chronic diseases such as diabetes, hypertension, heart failure, and chronic kidney disease.
In this article, we presented in more detail how a multidisciplinary team contributes to managing the CRM continuum, including a description of the different stages of CRM syndrome, and how different specialists can work together to optimize treatment.
KEYWORDS / КЉУЧНЕ РЕЧИ:
cardio-renal-metabolic continuum, a multidisciplinary team
REFERENCES / ЛИТЕРАТУРА:
- Marassi M, Fadini GP. The cardio-renal-metabolic connection: a review of the evidence. Cardiovascular diabetology. 2023;22(1):195. https://doi.org/10.1186/s12933-023-01937-x
- Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, et al. American Heart Association. Cardiovascular-Kidney-Metabolic Health: A Presidential Advisory From the American Heart Association. 2023;148(20):1606–35. https://doi.org/10.1161/CIR.0000000000001184
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group (2024). KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney international. 2024;105(S):S117–S314. https://doi.org/10.1016/j.kint.2023.10.018
- Fontes-Carvalho R, Santos-Ferreira D, Raz, I Marx N, Ruschitzka F, Cosentino F. Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin, European Journal of Preventive Cardiology. 2022;29(9):1352–60. https://doi.org/10.1093/eurjpc/zwab034
- Neuen BL, Heerspink HJL, Vart P, Claggett BL, Fletcher RA, Arnott C, et al. Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria. Circulation. 2024;149(6):450–62. https://doi.org/10.1161/CIRCULATIONAHA.123.067584
- Naaman SC, Bakris GL. Diabetic Nephropathy: Update on Pillars of Therapy Slowing Progression. Diabetes care. 2023;46(9):1574–86. https://doi.org/10.2337/dci23-0030
- ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes-2023. Diabetes care. 2023;46 (1):S191–S202. https://doi.org/10.2337/dc23-S011
- Chu CD, Xia F, Du Y, Singh R, Tuot DS, Lamprea-Montealegre JA, et al. Estimated Prevalence and Testing for Albuminuria in US Adults at Risk for Chronic Kidney Disease. JAMA network open. 2023;6(7):e2326230. https://doi.org/10.1001/jamanetworkopen.2023.26230
- Wanner C, Schaeffner E, Frese T, Weber C, Stahl P, Scherg F, et al. InspeCKD – Analyse zur Nutzung von Labordiagnostik im Kontext der chronischen Nierenerkrankung: Daten von Risikopatientinnen und -patienten in deutschen Hausarztpraxen [InspeCKD – Analysis of the use of diagnostics in patients at high risk for chronic kidney disease in German general practitioner (GP) practices]. MMW Fortschritte der Medizin. 2024;166(4):9–17. https://doi.org/10.1007/s15006-024-3684-y